−2.18USD
−255.10 MUSD
618.73 MUSD
98.51 M
About 10x Genomics, Inc.
Sector
Industry
CEO
Serge Saxonov
Website
Headquarters
Pleasanton
Employees (FY)
1.26 K
Founded
2012
FIGI
BBG007WX14X0
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company’s products include Single Cell Gene Expression, Immune Profiling, ATAC, and Genome. The company was founded by Serge Saxonov, Ben Hindson and Kevin D. Ness on July 2, 2012 and is headquartered in Pleasanton, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of TXG is 27.58 USD — it has decreased by 0.79% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange 10x Genomics, Inc. stocks are traded under the ticker TXG.
10x Genomics, Inc. is going to release the next earnings report on Apr 30, 2024. Keep track of upcoming events with our Earnings Calendar.
TXG stock is 5.51% volatile and has beta coefficient of 2.97. Check out the list of the most volatile stocks — is 10x Genomics, Inc. there?
TXG earnings for the last quarter are −0.79 USD per share, whereas the estimation was −0.46 USD resulting in a −71.58% surprise. The estimated earnings for the next quarter are −0.35 USD per share. See more details about 10x Genomics, Inc. earnings.
10x Genomics, Inc. revenue for the last quarter amounts to 153.64 M USD despite the estimated figure of 151.30 M USD. In the next quarter revenue is expected to reach 182.73 M USD.
Yes, you can track 10x Genomics, Inc. financials in yearly and quarterly reports right on TradingView.
TXG stock has fallen by 13.81% compared to the previous week, the month change is a 27.59% fall, over the last year 10x Genomics, Inc. has showed a 48.65% decrease.
TXG net income for the last quarter is −48.95 M USD, while the quarter before that showed −92.99 M USD of net income which accounts for 47.36% change. Track more 10x Genomics, Inc. financial stats to get the full picture.
Today 10x Genomics, Inc. has the market capitalization of 3.33 B, it has decreased by 1.20% over the last week.
No, TXG doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, TXG shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade 10x Genomics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 23, 2024, the company has 1.26 K employees. See our rating of the largest employees — is 10x Genomics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So 10x Genomics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating 10x Genomics, Inc. stock shows the sell signal. See more of 10x Genomics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on 10x Genomics, Inc. future price: according to them, TXG price has a max estimate of 65.00 USD and a min estimate of 30.00 USD. Read a more detailed 10x Genomics, Inc. forecast: see what analysts think of 10x Genomics, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. 10x Genomics, Inc. EBITDA is −160.73 M USD, and current EBITDA margin is −25.58%. See more stats in 10x Genomics, Inc. financial statements.